2. Immunology/Inflammation Cytoskeleton
  3. CD22 NOD-like Receptor (NLR) Interleukin Related Integrin
  4. Suciraslimab

Suciraslimab  (Synonyms: SM03)

Cat. No.: HY-P990781 Purity: 97.42%
COA
SDS
Technical Support

Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation. Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).

For research use only. We do not sell to patients.

CAS No. : 2415439-63-1

Size Price Stock Quantity
1 mg In-stock
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Suciraslimab Related Antibodies

Top Publications Citing Use of Products

View All NOD-like Receptor (NLR) Isoform Specific Products:

View All Isoforms
NLRP3 NLRP1 NOD1 NOD2

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

View All Integrin Isoform Specific Products:

View All Isoforms
αvβ1 αvβ3 αvβ5 αvβ6 αvβ8 α5β1 α1β1 α2β1 α4β1 α9β1 αIIbβ3 α4β7 αLβ2

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation[1]. Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target[1]

IL-23

 

IL-12

 

IL-1β

 

In Vitro

Suciraslimab (0.1 μg/mL; overnight) inhibits the secretion of interleukin-1β (IL-1β) induced by Amyloid β (Aβ) in human monocyte-derived microglia-like cells (MDMi) and PBMC[1].
Suciraslimab (0.1 μg/mL; 4 h) enhances phagocytosis of FITC-Aβ by the human microglial cell line HMC-3 and the Phorbol 12-myristate 13-acetate (HY-18739)-differentiated human oligodendrocyte cell line MO3.13[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Suciraslimab Related Antibodies
In Vivo

Suciraslimab (15 mg/kg; i.v.; once a week) alleviates Aβ-induced neuroinflammation in human CD22 transgenic mice[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Human CD22 transgenic mice (C57BL/6JGpt-Cd22em1Cin(hCD22)/Gpt), male, 6-9 months old, with intracerebroventricular injection of oligomeric Aβ to induce neuroinflammation[1]
Dosage: 15 mg/kg
Administration: Intravenous injection; once a week
Result: Restored spatial working memory.
Downregulated the expression of genes related to leukocyte migration and sialic acid binding in the brain.
Reduced the levels of chemokines such as CX3CL1, CCL24, and CCL4 in the cortex.
Clinical Trial
Gene ID

933  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

146.16 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Suciraslimab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • IgG1-kappa
Biological Activity
  • Flow Cytometry analysis of Raji cells labelling Siglec-2/CD22 (red) with Suciraslimab (anti-Siglec-2/CD22) (HY-P990781). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
  • Immobilized Siglec-2/CD22 Protein, Human can bind Suciraslimab. The EC50 for this effect is 4.412 ng/mL.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Suciraslimab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Suciraslimab2415439-63-1SM03SM 03SM-03CD22NOD-like Receptor (NLR)Interleukin RelatedIntegrinSiglec 2ILInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Suciraslimab
Cat. No.:
HY-P990781
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.